{"filings":[{"id":109510,"accession_number":"0001493152-26-008879","cik":1834105,"company_name":"IMPACT BIOMEDICAL INC.","ticker":"IBO","form_type":"8-K","filed_at":"2026-03-04T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Impact BioMedical amends merger deal with Dr Ashleys; extends deadline to July 1, 2026","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Amendment adds 53,000 and 75,000 PubCo ordinary shares to be issued to DSS, Inc. at closing.","Total Company Share Consideration set at 169,560,000 PubCo shares (94.20% of post-closing outstanding).","Termination date extended from March 31, 2026 to July 1, 2026, with mutual extension option.","Impact must seek board approval to co-sign loan agreements requested by PubCo or Dr Ashleys before effective time.","Supporting stockholders now hold 92,980,843 Impact shares (88.87% fully diluted); holdings of DSS, Inc. and DSS BioHealth updated."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":52843185.3131,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":126020,"accession_number":"0001493152-25-021066","cik":1834105,"company_name":"IMPACT BIOMEDICAL INC.","ticker":"IBO","form_type":"8-K","filed_at":"2025-11-06T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Impact Biomedical shareholders elect directors, ratify auditor, approve say-on-pay at 2025 annual meeting","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["All eight director nominees elected with ~61.5M votes each; broker non-votes of ~2.7M.","Ratification of Grassi & Co. as auditor for FY2025 received 64.1M votes for, 174k against.","Advisory say-on-pay approved: 61.5M for, 108k against, 2.7M broker non-votes.","Quorum of 88.5% of outstanding shares (64.3M shares) represented at the meeting."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.15,"market_cap_usd":52843185.3131,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":126019,"accession_number":"0001493152-25-019734","cik":1834105,"company_name":"IMPACT BIOMEDICAL INC.","ticker":"IBO","form_type":"8-K","filed_at":"2025-10-27T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"DSS BioHealth converts Series A Preferred into 60.5M common shares of Impact BioMedical","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["DSS BioHealth Security converted its Series A Convertible Preferred Stock into 60,496,041 shares of common stock.","Conversion was elected under Section 6 of the Certificate of Designation, effective after 75-day holding period.","The converted shares represent a significant increase in diluted share count, potentially impacting existing shareholders."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":52843185.3131,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":142750,"accession_number":"0001641172-25-021085","cik":1834105,"company_name":"IMPACT BIOMEDICAL INC.","ticker":"IBO","form_type":"8-K","filed_at":"2025-07-28T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Impact BioMedical to issue 31.9M shares to DSS to settle $12M debt","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Issued 31,939,778 shares of common stock to DSS Inc. to fully satisfy $12M revolving promissory note from March 2023.","Original note was amended Jan 2024 to extend maturity to Sept 30, 2023, eliminate advance feature, set repayment terms, adjust interest to WSJ Prime + 0.5%.","Shares are freely tradeable and settle all amounts owed under the note and any additional support between June 21, 2025 and closing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":52843185.3131,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":160838,"accession_number":"0001641172-25-016002","cik":1834105,"company_name":"IMPACT BIOMEDICAL INC.","ticker":"IBO","form_type":"8-K","filed_at":"2025-06-23T23:59:59+00:00","items":["1.01","7.01","9.01"],"status":"ready","headline":"Impact BioMedical announces reverse merger with Dr Ashleys; shareholders to receive 4.80% of combined entity","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Impact BioMedical (IBO) will merge with Dr Ashleys via a reverse merger; existing Impact shareholders receive 4.80% of the new PubCo's ordinary shares.","Dr Ashleys shareholders get 94.20% of PubCo; Dr Ashleys management will control the combined company's board and operations.","86.81% of Impact's shareholders (by as-converted shares) have signed a voting agreement to approve the deal.","Closing conditions include Impact having at least $10,000 net cash and zero net debt, and NYSE American listing approval.","The combined entity will be renamed Dr Ashleys Limited and continue trading on NYSE American under a new name."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":1.0,"calibrated_materiality_score":1.0,"market_cap_usd":52843185.3131,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":160837,"accession_number":"0001641172-25-002577","cik":1834105,"company_name":"IMPACT BIOMEDICAL INC.","ticker":"IBO","form_type":"8-K","filed_at":"2025-04-03T23:59:59+00:00","items":["1.01"],"status":"ready","headline":"DSS withdraws from $13.2M debt conversion agreement; no shares issued","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["DSS withdrew from Debt Conversion Agreement, originally dated March 24, 2025.","Promissory Note principal balance was $13,176,477.03.","No shares of common stock have been issued under the agreement.","Withdrawal attributed to current market conditions."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":52843185.3131,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":179038,"accession_number":"0001641172-25-001060","cik":1834105,"company_name":"IMPACT BIOMEDICAL INC.","ticker":"IBO","form_type":"8-K","filed_at":"2025-03-28T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Impact Biomedical settles $8.7M debt with 2.4M shares at $3.60/share","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Debt conversion with DSS Inc. settles $8,697,142.80 of the $13,176,477.03 principal balance.","Issued 2,415,873 shares of common stock at $3.60 per share, equal to March 24 closing price.","Original promissory note principal was $12,000,000; amended September 16, 2024.","Settlement reduces outstanding debt by 66% while diluting existing shareholders by approximately 2.4M shares."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":52843185.3131,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":179037,"accession_number":"0001493152-25-010190","cik":1834105,"company_name":"IMPACT BIOMEDICAL INC.","ticker":"IBO","form_type":"8-K","filed_at":"2025-03-13T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Impact Biomedical appoints Chan Heng Fai Ambrose to board of directors","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Appointed March 11, 2025, effective same date; over 45 years financial/equity investment experience.","Current director/chair roles include Alset International, DSS Inc., Hapi Metaverse, LiquidValue Development, Alset Inc., Sharing Services Global, HWH International, Value Exchange International.","No arrangement or understanding with any other person for appointment; no family relationships or related-party transactions per Item 404(a)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":52843185.3131,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":179036,"accession_number":"0001493152-25-004161","cik":1834105,"company_name":"IMPACT BIOMEDICAL INC.","ticker":"IBO","form_type":"8-K","filed_at":"2025-01-29T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Impact Biomedical CEO presents investor slide deck on Jan 29, 2025; no details available","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["Slide package furnished as Exhibit 99.1 not included in filing text; no specifics provided.","CEO Frank D. Heuszel provided investor information on January 29, 2025.","No financial metrics, guidance, or operational updates disclosed in the filing body."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.0,"calibrated_materiality_score":0.0,"market_cap_usd":52843185.3131,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":195712,"accession_number":"0001493152-24-043558","cik":1834105,"company_name":"IMPACT BIOMEDICAL INC.","ticker":"IBO","form_type":"8-K","filed_at":"2024-11-04T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Impact Biomedical furnishes investor presentation; no specific financial updates disclosed","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["COO Mark Suseck began delivering investor presentations on November 4, 2024.","Presentation slide deck furnished as Exhibit 99.1; no new financial data or guidance in the filing.","Company does not assume obligation to update the presentation information.","No material operational metrics, revenue, or earnings figures provided in the 8-K."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":52843185.3131,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":195711,"accession_number":"0001493152-24-040465","cik":1834105,"company_name":"IMPACT BIOMEDICAL INC.","ticker":"IBO","form_type":"8-K","filed_at":"2024-10-08T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Impact Biomedical enters three-year CEO employment agreement with Frank Heuszel","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Term from Oct 3, 2024 to Oct 3, 2027; base salary $200K year 1, $250K years 2 and 3.","Mandatory bonus: $150K year 1, $100K each year 2 and 3; discretionary bonuses eligible.","Option grant of 300,000 shares at $3.00/share under 2023 Equity Incentive Plan.","Agreement defines termination for cause and good reason; executive remains CEO, Chairman, President."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":52843185.3131,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":211984,"accession_number":"0001493152-24-036888","cik":1834105,"company_name":"IMPACT BIOMEDICAL INC.","ticker":"IBO","form_type":"8-K","filed_at":"2024-09-17T23:59:59+00:00","items":["1.01","8.01","9.01"],"status":"ready","headline":"Impact Biomedical closes IPO of 1.5M shares at $3.00, net proceeds ~$3.76M","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["IPO of 1,500,000 common shares at $3.00 per share; net proceeds to company ~$3,764,500 after discounts and expenses.","Shares began trading on NYSE American on Sept 16, 2024 under ticker IBO; offering closed Sept 17, 2024.","Underwriters granted 45-day option to buy up to 225,000 additional shares at IPO price less discount.","Representative's warrants issued for 75,000 shares (5% of offering) at $3.75/share, exercisable from 9 months to 3 years.","Company and insiders subject to 6-month lock-up on share sales after effective date."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":52843185.3131,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":230808,"accession_number":"0001493152-24-023096","cik":1834105,"company_name":"IMPACT BIOMEDICAL INC.","ticker":"IBO","form_type":"8-K","filed_at":"2024-06-07T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Director Heng Fai Ambrose Chan resigns; Jason T. Grady appointed to board","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Heng Fai Ambrose Chan resigned as director effective June 6, 2024, with no disagreement.","Board appointed Jason T. Grady as director effective June 6, 2024.","Grady is COO of DSS, Inc., President of Premier Packaging, President/COO of DSS Wealth Management and BioLife Science.","No arrangement or understanding regarding Grady's appointment; no family relationship or related party transaction."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":52843185.3131,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}